BYSI BeyondSpring Inc.
USHealthcareAs of 2026-10-07 11:11
Why BYSI matters now
BeyondSpring Inc. (BYSI) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.65 with -5.73% on the session and $26.8M in market capitalization; recent performance reads 1-month +24.81% and YTD -1.23%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.2M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.8%.
The latest indexable market news headline is "BeyondSpring Wins FDA Fast Track for Plinabulin Lung Cancer Program" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Huang Lan filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.92
P/S
0.00
EV/EBITDA
-7.79
DCF Value
$0.18
FCF Yield
-28.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
23.8%
ROA
-41.5%
ROIC
-136.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.2M | $-0.05 |
| Q4 2025 | $0.00 | $-2.1M | $-0.05 |
| FY 2025 | $0.00 | $-8.0M | $-0.20 |
| Q3 2025 | $0.00 | $-1.5M | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.42
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.